KEYNOTE-042 Final Analysis: Pembrolizumab vs Chemotherapy in First-Line PD-L1-Positive Locally Advanced/Metastatic NSCLC

Kubota Kaoru, G. Lopes, Dang Thi Thanh Thao, Penrod Justina, M Kowalski Dariusz, K Laktionov Konstantin, Iveta Kudaba(Riga East University Hospital), DE Castro Gilberto, Surekha Tony, Z Turna Hande, Vichien Srimuninnimit(Siriraj Hospital), Chul-Cho Byoung, Bogusława Karaszewska(State University of Applied Sciences in Konin), Lina Yin(University of California, Los Angeles), Bondarenko Igor, Yi-Long Wu, Christian Caglevic

日本臨床腫瘍学会学術集会(CD-ROM)

January 1, 2019

Cited by 0

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.4k

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2012|3k

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

|New England Journal of Medicine|2014|2.7k

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

|New England Journal of Medicine|2019|1.4k

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2018|1.3k